Telix Pharmaceuticals & DKFZ partner for image-guided prostate surgery
Category: #health  By Pankaj Singh  Date: 2019-08-05
  • share
  • Twitter
  • Facebook
  • LinkedIn

Telix Pharmaceuticals & DKFZ partner for image-guided prostate surgery

· Telix would work with DKFZ for required translational research to evaluate technology in surgical settings.

· Agreement has a negotiated and exclusive option to license the new technology for commercial-level development.

Telix Pharmaceuticals Limited, (Telix), an Australian biopharmaceutical company aimed at the development of therapeutic and diagnostic products based upon molecularly-targeted radiation (MTR) or targeted radiopharmaceuticals, has reportedly announced a new collaboration with German Cancer Research Center (DKFZ) for prostate cancer through image-guided surgery.

Under this collaboration, Telix would work with DKFZ and associated researchers to carry out required translational research studies to assess the technology in surgical settings.

CEO of Telix Group, Dr. Christian Behrenbruch stated that the amazing research of the scientists at DKFZ & Heidelberg has a lot of potential in developing the efficiency and quality of utilizing image-guided techniques for conducting robotic surgery. Previously, Telix has aimed at use of PSMA imaging in post-prostatectomy biochemical renewal settings. Dr. Christian added that this partnership would explore how Image-Guided surgery and PET could be used to enhance results from prostatectomy, further extending the impact of molecular imaging while handling prostate cancer.

Heidelberg University Clinic and DKFZ researchers created a next-generation radiotracer made on the basis of 68Ga-PSMA-11 that contains a fluorophore along with the capability to molecularly target radiation for imaging with Positron Emission Tomography (PET). The outcome is a technology that can concurrently image PET with prostate cancer and facilitate guidance for intra-operative surgical development through fluorescence imaging.

Dr. Ann-Christin Baranski, principal investigator at DKFZ and scientist at German Cancer Consortium and Nuclear Medicine department at University Hospital of Freiburg stated that researchers at Telix have made immense progress in the commercialization of PSMA-11 PET imaging, which was a technology initially developed at DKFZ . The company believes that Telix is a ideal commercial partner for this new technology and looks forward to work with Telix to understand the impact of the technology on patients in future.

The collaboration agreement has a negotiated and exclusive option to license the new technology for commercial-level development.

Source Credits: https://www.globenewswire.com/news-release/2019/08/05/1896616/0/en/Telix-Pharmaceuticals-and-German-Cancer-Research-Center-DKFZ-Enter-into-Collaboration-and-Option-Agreement-for-Image-Guided-Prostate-Surgery.html



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

Flipkart launches Loyalty Program across 5,000 retail outlets in India
Flipkart launches Loyalty Program across 5,000 retail outlets in India
By Pankaj Singh

E-commerce giant Flipkart has recently launched SuperCoin Pay, a system of currency which its customers will have the right to use across tons of retail stores in the country. Flipkart is betting on its loyalty program...

Sirnaomics reveals dose administration of 1st patient in STP705 trial
Sirnaomics reveals dose administration of 1st patient in STP705 trial
By Pankaj Singh

Sirnaomics, Inc., a clinical-stage biopharmaceutical company, has recently announced the dose administration of the 1st patient in a Phase 2a clinical trial of STP705. STP705 is a lead drug candidate develop...

Pfizer’s XALKORI®) Approved by US FDA for ALK-positive ALCL treatment
Pfizer’s XALKORI®) Approved by US FDA for ALK-positive ALCL treatment
By Pankaj Singh

The pharma giant Pfizer Inc. has reportedly declared that the U.S. Food and Drug Administration (US FDA) has approved the sNDA (supplemental New Drug Application) for XALKORI® (crizotinib) for the treatment of chil...